ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

NCI CTEP-Approved Trials For the Month of August

August 29, 2014

FDA Approves Two Oral Drugs For Metastatic Melanoma

June 28, 2013

Remarks on HPV Vaccines, SPORE Funds Create Controversy for NCI’s John Niederhuber.

April 14, 2006

AACR Statement on Precancers Plays Key Role in NCI Agenda

May 30, 2003

Chemoprevention Concept Approved By DCPC Bard Uses Biological Markers To Assess Risk Modulation

September 27, 1985

DCT Board Committee Drawing Up Plans On How To Spend Biological Response Modifiers Money

August 31, 1979